The Goldman Sachs Group Initiates Coverage on Silence Therapeutics (NASDAQ:SLN)

The Goldman Sachs Group initiated coverage on shares of Silence Therapeutics (NASDAQ:SLN) in a research note released on Tuesday, MarketBeat reports. The firm issued a sell rating and a $6.00 price objective on the stock.

A number of other equities analysts also recently issued reports on SLN. BMO Capital Markets reiterated an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Wednesday, January 29th. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.00.

Silence Therapeutics Price Performance

Shares of NASDAQ SLN opened at $4.16 on Tuesday. The company has a 50-day moving average price of $6.26 and a 200-day moving average price of $12.96. The stock has a market capitalization of $124.51 million, a P/E ratio of -2.65 and a beta of 1.05. Silence Therapeutics has a 1 year low of $4.06 and a 1 year high of $27.72.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in Silence Therapeutics in the fourth quarter worth about $134,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Silence Therapeutics during the 4th quarter worth approximately $69,000. FNY Investment Advisers LLC bought a new stake in shares of Silence Therapeutics in the 4th quarter worth approximately $120,000. GAMMA Investing LLC lifted its stake in Silence Therapeutics by 609.2% in the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after purchasing an additional 5,233 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd grew its holdings in Silence Therapeutics by 22.9% during the third quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company’s stock valued at $383,000 after purchasing an additional 3,923 shares during the period. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.